# Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

Study · id `cardio:ct-nct01807221` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01807221](<https://clinicaltrials.gov/study/NCT01807221>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01807221

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1066 participants.

## Technical summary

Registry record NCT01807221. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-17 (actual); primary completion 2014-11-11 (actual). Results posted on 2021-06-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1066 participants (enrolled count; ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Started: 2013-06-17 (actual) (ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Primary completion: 2014-11-11 (actual) (ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Completion: 2014-12-09 (actual) (ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Results first posted: 2021-06-15 (ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Bulgaria; Canada; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; Israel; Italy; Lithuania; Netherlands; Norway; Poland; Portugal; South Africa; South Korea; Spain; Sweden; Taiwan; Türkiye (ClinicalTrials.gov record NCT01807221, source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01807221-2021-07-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
- Acronym: ARTS-HF
- Condition: Heart Failure
- Intervention (Drug): Finerenone (BAY94-8862)
- Intervention (Drug): Placebo
- Intervention (Drug): Inspra (eplerenone)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (`cardio:pubmed-27130705`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e8ba0e3c23b3599a55d36784835a88272127ef6441c8f0866b719e3476f2afcd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
